Welcome to our dedicated page for Horizon Flexible Income ETF news (Ticker: FLXN), a resource for investors and traders seeking the latest updates and insights on Horizon Flexible Income ETF stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Horizon Flexible Income ETF's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Horizon Flexible Income ETF's position in the market.
Flexion Therapeutics (Nasdaq: FLXN) announced its plans to report second-quarter 2020 financial results on August 5, 2020, after U.S. market close. The company focuses on developing innovative, local therapies aimed at treating musculoskeletal conditions, particularly osteoarthritis. This upcoming financial report may provide insights into the company's performance and future outlook.
Flexion Therapeutics reported preliminary net sales of ZILRETTA at $15.4 million for Q2 2020, with demand increasing month-over-month. Total purchases by healthcare providers reached approximately 36,700 units, aligning with the first quarter. The company plans to resume ZILRETTA manufacturing in Q4 after a voluntary pause due to COVID-19. Flexion's management expressed satisfaction with sales performance amid pandemic uncertainties, highlighting ZILRETTA's role in providing pain relief for osteoarthritis knee pain.
Flexion Therapeutics, Inc. (Nasdaq: FLXN) announced that its CEO, Michael Clayman, M.D., will participate in a virtual fireside chat at the BMO 2020 Prescriptions for Success Healthcare Conference. The event is scheduled for June 23, 2020, starting at 9:30 a.m. ET. Interested parties can access the live webcast on Flexion's website. Flexion Therapeutics focuses on creating innovative local therapies for musculoskeletal conditions, particularly targeting osteoarthritis.
Flexion Therapeutics (Nasdaq: FLXN) announced a public offering of $75 million of its common stock, with a potential 15% over-allotment option for underwriters. The offering is managed by Goldman Sachs and Credit Suisse and is contingent on market conditions. Proceeds from the offering will be used to support the company's innovative therapies targeting musculoskeletal conditions. The offering is filed under a shelf registration statement with the SEC, ensuring compliance and availability of necessary documentation.
Flexion Therapeutics (Nasdaq: FLXN) announced that Dr. Michael Clayman, President and CEO, will engage in an analyst-led fireside chat at the RBC Capital Markets 2020 Virtual Global Healthcare Conference. This event is scheduled for 10:55 a.m. ET on May 19, 2020. To access the live webcast, visit Flexion's website. Flexion focuses on developing novel therapies for musculoskeletal conditions, primarily targeting osteoarthritis.
Flexion Therapeutics (FLXN) reported Q1 2020 net sales of $20.1 million for its product ZILRETTA, up from $10.6 million in Q1 2019. The company incurred a net loss of $36.8 million, improving from $41.5 million the previous year. Operating expenses are forecasted to be between $167 million and $177 million for 2020 due to COVID-19 impacts. Flexion has discontinued its Phase 2 trial for ZILRETTA in shoulder osteoarthritis and is suspending the Phase 1 trial for FX201. A $10 million upfront payment was received from HK Tainuo for the development of ZILRETTA in Greater China.
Summary not available.
Summary not available.
Summary not available.